Ariadne Genomics, Inc. Licenses PathwayStudio® To UCB To Support The Discovery Of New Drug Targets And Biomarkers

January 11, 2006 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Ariadne Genomics, Inc., today announced that UCB (Euronext: UCB) has licensed its PathwayStudio® software to support early stages of the drug discovery process - target identification and biomarker research.

Twitter
LinkedIn
Facebook
Email
Print

Alliances